Dapagliflozin in patients with COVID-19: truth or dare
- PMID: 34302746
- PMCID: PMC8294806
- DOI: 10.1016/S2213-8587(21)00206-0
Dapagliflozin in patients with COVID-19: truth or dare
Conflict of interest statement
We declare no competing interests.
Comment on
-
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Diabetes Endocrinol. 2021 Sep;9(9):586-594. doi: 10.1016/S2213-8587(21)00180-7. Epub 2021 Jul 21. Lancet Diabetes Endocrinol. 2021. PMID: 34302745 Free PMC article. Clinical Trial.
References
-
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. - PubMed
-
- Rossello X, Yellon DM. A new era in the management of type 2 diabetes: is cardioprotection at long last a reality? Int J Cardiol. 2017;228:198–200. - PubMed
-
- Kosiborod M, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 doi: 10.1016/S2213-8587(21)00180-7. published online July 21. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical